Kevin Eisele, managing director on the Equity Capital Markets team at William Blair, was quoted in the Wall Street Journal’s Venture Capital Pro, providing comment on the potential for increased venture capital activity in Chinese companies and investment opportunities in the biopharma sector.
“There’s certainly a view that the incoming administration might look for regulatory paths to curb that level of activity and put some kind of protectionism in place to reallocate those dollars,” Eisele said.